Abstract
HER2 overexpression is a good predictive marker of HER2 targeted therapy, which means that HER2 therapy will be very effective in reducing the size of HER2 positive breast cancers. Therefore, the size of HER2 positive breast cancer can easily be reduced in patients who wish to have a breast-conserving operation, and potentially improves the outcome of patients if pathologic complete response (PCR) can be achieved.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
